Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanoma.
Haas L, Elewaut A, Gerard CL, Umkehrer C, Leiendecker L, Pedersen M, Krecioch I, Hoffmann D, Novatchkova M, Kuttke M, Neumann T, da Silva IP, Witthock H, Cuendet MA, Carotta S, Harrington KJ, Zuber J, Scolyer RA, Long GV, Wilmott JS, Michielin O, Vanharanta S, Wiesner T, Obenauf AC.
Haas L, et al. Among authors: leiendecker l.
Nat Cancer. 2021 Jul;2(7):693-708. doi: 10.1038/s43018-021-00221-9. Epub 2021 Jul 15.
Nat Cancer. 2021.
PMID: 35121945
Free PMC article.